This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

BEXSERO OFFERS THE FASTEST MenB SERIES COMPLETION ON THE MARKET1,2

1 Month

Only BEXSERO has a 2-dose schedule for every eligible patient, regardless of risk level1,2

Only BEXSERO offers patients the fastest MenB series completion—with a dosing schedule that could be finished within a typical summer break, or even during winter break for college students.1 After receiving the first dose, patients can receive the second dose after a 1-month period, helping you vaccinate adolescents who infrequently visit primary care offices.1,3 

BEXSERO comes in a glass prefilled syringe and is administered as a 0.5-mL intramuscular injection.1 

 

Indication

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

 

What is the MenB vaccination rate of your practice?

Be sure to check your records—the numbers may be lower than you think. According to 2019 CDC survey data, only 21.8% of 17-year-olds received at least 1 dose of a MenB vaccine.4

 

Start the series. Stay the course.

Do your patients receive both doses? Take these important steps to ensure they complete the series:

  • Schedule the second dose appointment as soon as your patient receives the first dose
  • Set up follow-up reminders to help patients stay on track
  • Click here to sign up for the GSK Vaccine Reminder Service for MenB

CDC=Centers for Disease Control and Prevention; MenB=meningococcal serogroup B.

 

References

  1. Prescribing Information for BEXSERO.
  2. Prescribing Information for Trumenba.
  3. Centers for Disease Control and Prevention. Vaccine recommendations and guidelines of the ACIP: vaccination programs. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/programs.html. Reviewed July 12, 2017. Accessed September 21, 2020.
  4. Elam-Evans LD, Yankey D, Singleton JA, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years—United States, 2018. MMWR. 2020;69(33):1109-1116.

Indication

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

Important Safety Information for BEXSERO

  • BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO
  • Appropriate observation and medical treatment should always be readily available in case of an anaphylactic reaction following the administration of the vaccine
  • The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions
  • Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
  • The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
  • Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains
  • Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with BEXSERO
  • Vaccination with BEXSERO may not result in protection in all vaccine recipients

Please see full Prescribing Information for BEXSERO.

Trademarks are property of their respective owners.